Medtronic plc (MDT)
MiniMed Group: Medtronic's Diabetes Business Does Not Convince
MiniMed Group trades at a modest 2x sales but struggles with persistent operating losses despite 10-15% annual revenue growth. The IPO priced below range at $20/share, raising $560M; Medtronic retains 90% ownership, and MiniMed holds $350M net cash. MiniMed faces intense competition and execution risks as a standalone entity, with profitability elusive despite a large addressable diabetes market.
Medtronic's diabetes unit MiniMed valued at $5.3 billion as shares fall in Nasdaq debut
Shares of MiniMed , the diabetes business of medical device maker Medtronic , opened 4.8% below their offer price in their Nasdaq debut on Friday, valuing it at $5.3 billion.
Medtronic's diabetes unit MiniMed raises $560 million in US IPO
MiniMed, the diabetes business of medical device maker Medtronic , said on Thursday it has raised $560 million in its U.S. initial public offering.
Medtronic Debuts MiniMed Go Smart MDI With Simplera Sensor in Europe
MDT launches MiniMed Go Smart MDI with the Simplera sensor in Europe, advancing connected insulin care as the Diabetes unit's IPO plans progress.
1 Reason I'd Buy Medtronic Stock and Never Sell
Medtronic is one of the world's largest medical device companies. Its dividend streak speaks volumes about the strength of its business.
Medtronic's “Textbook” Reversal: How High Can It Really Go in 2026?
Medtronic's NYSE: MDT stock price is amid a textbook reversal, having formed a Head & Shoulders Pattern and broken to fresh highs, confirming the baseline as a critical pivot point. The question now is how high the stock might rise.
Medtronic plc (MDT) Q3 2026 Earnings Call Transcript
Medtronic plc (MDT) Q3 2026 Earnings Call Transcript
MDT Stock Up on Q3 Earnings and Revenue Beat, Margins Down
Medtronic tops Q3 revenue and EPS estimates as Cardiovascular and Diabetes drive growth, but margin contraction tempers the upbeat quarter.
Compared to Estimates, Medtronic (MDT) Q3 Earnings: A Look at Key Metrics
The headline numbers for Medtronic (MDT) give insight into how the company performed in the quarter ended January 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Medtronic Just Posted Its Best Quarter in 2.5 Years
Medtronic (NYSE: MDT) delivered its strongest enterprise revenue growth in 10 quarters, posting 8.7% reported growth (6.0% organic) for Q3 fiscal 2026.
Medtronic (MDT) Q3 Earnings and Revenues Top Estimates
Medtronic (MDT) came out with quarterly earnings of $1.36 per share, beating the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $1.39 per share a year ago.
Medtronic Profit Falls Despite Higher Revenue
Medtronic said profit fell in its fiscal third quarter as costs rose and the company invested more money into the business, offsetting higher revenue.
